HCV infection of peripheral blood mono nuclear cells and serum levels of soluble ICAM-1 in patients treated with interferon

Taliani, Gloria; Badolato, M. C.; Bozza, A.; Poliandri, G.; Duca, F.; Pasquazzi, C.; Lecce, R.; Bruni, Renato; Bac, Carlo De

doi:10.1007/s007050050101

Cited by 3 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, a second histological score according to Desmet et al [27] was calculated, which distinguishes between grading (score 0-18), obtained by the sum of histological changes expressed by Knodell's numerical scoring system (periportal necrosis, intralobular degeneration and portal inflammation), and staging, an expression of fibrosis (score 0-4). Histological diagnosis was performed according to Desmet et al [27]: minimal chronic hepatitis (grading 1-3), mild chronic hepatitis (grading 4-8), moderate chronic hepatitis (grading 9-12) or severe chronic hepatitis (grading [13][14][15][16][17][18]. If staging was 3 (independently of grading), the classification was hepatitis with severe fibrosis; if staging was 4, the classification was liver cirrhosis.…”

Section: Methodsmentioning

confidence: 99%

Circulating Intercellular Adhesion Molecule-1 in Chronic Hepatitis C Patients with Normal or Elevated Aminotransferase before and after Alpha-Interferon Treatment

Montalto

Giannitrapani²,

Soresi³

et al. 2003

Intervirology

View full text Add to dashboard Cite

Objectives: Intercellular adhesion molecule-1 (ICAM-1) plays a fundamental role during liver inflammation. In fact, weak ICAM-1 expression is physiologically restricted to the endothelium of portal vessels and to sinusoidal lining cells, but it becomes markedly evident on sinusoidal lining cells and at the surface of hepatocytes during inflammatory liver diseases. The aim of this study was to evaluate the behaviour of soluble ICAM-1 (sICAM-1) in chronic hepatitis C (CH-C) patients with persistently normal aminotransferase in comparison with patients with CH-C and elevated aminotransferase, and its changes during α-interferon (IFN) therapy. Immunohistochemical localization of ICAM-1 was also performed on liver tissue specimens of both groups. Methods: Sixty subjects were divided into 3 groups: group A included 19 patients with CH-C and persistently normal aminotransferase; group B included 21 patients with CH-C and persistently elevated aminotransferase levels, and group C included 20 healthy subjects representing the control group. The first two groups were treated with recombinant α-IFN 2b at a dose of 6 MU 3 times a week for 3 months and followed up with 3 MU 3 times a week for another 3 months. Results: Baseline values of serum ICAM-1 in groups A and B were significantly higher than those in group C (p < 0.0001). The median baseline value of sICAM-1 in group A (525.0 ng/ml) was lower than that of group B (561.0 ng/ml), but the difference was not statistically significant. Furthermore, there was a trend toward higher ICAM-1 values as histological severity increased (Mantel-Haenszel χ² 8.8, p < 0.003). Post-treatment sICAM-1 serum values showed a marked decrease in both groups, but only among responder patients, while ICAM-1 levels were unchanged in non-responders. Immunohistochemical localization showed no staining for ICAM-1 in normal liver specimens, while there was a quite similar staining for ICAM-1 in the two groups of patients, consistent with an inflammatory process. Conclusions: This study shows that circulating ICAM-1 levels in most patients with CH-C and persistently normal aminotransferase are higher than those in a control group and the fact that ICAM-1 molecules are also expressed on the hepatocyte membrane suggests that they could play an important role, in association with other molecules, in the intercellular adhesion processes during the induction and maintenance phases of the immune response. In both groups, only patients responding to α-IFN therapy showed a marked decrease in serum ICAM-1 below baseline values.

show abstract

Section: Methodsmentioning

confidence: 99%

Circulating Intercellular Adhesion Molecule-1 in Chronic Hepatitis C Patients with Normal or Elevated Aminotransferase before and after Alpha-Interferon Treatment

Montalto

Giannitrapani²,

Soresi³

et al. 2003

Intervirology

View full text Add to dashboard Cite

show abstract

Serum Level of Soluble Intercellular Adhesion Molecule 1 in Patients with Chronic Liver Disease Related to Hepatitis C Virus: A Prognostic Marker for Responses to Interferon Treatment

et al. 2000

View full text Add to dashboard Cite

Intercellular adhesion molecule 1 (ICAM-1) is a marker of inflammation and tissue damage. Levels of soluble ICAM-1 (sICAM-1) were measured in 71 patients with chronic C hepatitis treated with interferon (IFN)-alpha-2a, at baseline and at every 3 months of therapy, and in 42 normal control subjects. The levels of sICAM-1 were significantly higher in the patient than in the control subject group, particularly among cirrhotics. Baseline sICAM-1 levels were similar in responders and nonresponders. By contrast, the concentration of sICAM-1 decreased significantly only in responders during the first 3 months of therapy. The probability of response to treatment, analyzed by Kaplan-Meier analysis, was much higher in the group showing a decrease of sICAM-1 than in the patients who did not show such a decrease. In conclusion, a "longitudinal" evaluation of serum levels of sICAM-1 in the first period of treatment is particularly useful in the identification of patients with high significant probability of response to treatment.

show abstract

Monocyte chemotactic protein-1 and soluble adhesion molecules as possible prognostic markers of the efficacy of antiviral treatment in chronic hepatitis C

Panasiuk¹

2004

WJG

View full text Add to dashboard Cite

show abstract

HCV infection of peripheral blood mono nuclear cells and serum levels of soluble ICAM-1 in patients treated with interferon

Cited by 3 publications

References 16 publications

Circulating Intercellular Adhesion Molecule-1 in Chronic Hepatitis C Patients with Normal or Elevated Aminotransferase before and after Alpha-Interferon Treatment

Circulating Intercellular Adhesion Molecule-1 in Chronic Hepatitis C Patients with Normal or Elevated Aminotransferase before and after Alpha-Interferon Treatment

Serum Level of Soluble Intercellular Adhesion Molecule 1 in Patients with Chronic Liver Disease Related to Hepatitis C Virus: A Prognostic Marker for Responses to Interferon Treatment

Monocyte chemotactic protein-1 and soluble adhesion molecules as possible prognostic markers of the efficacy of antiviral treatment in chronic hepatitis C

Contact Info

Product

Resources

About